- Home
- SNTG vs WINT Comparison
SNTG vs WINT Comparison
Compare SNTG & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- WINT
- Stock Information
- Founded
- SNTG 2009
- WINT 1992
- Country
- SNTG China
- WINT United States
- Employees
- SNTG N/A
- WINT N/A
- Industry
- SNTG Finance: Consumer Services
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNTG Finance
- WINT Health Care
- Exchange
- SNTG Nasdaq
- WINT Nasdaq
- Market Cap
- SNTG 5.4M
- WINT 5.3M
- IPO Year
- SNTG 2021
- WINT 1995
- Fundamental
- Price
- SNTG $1.88
- WINT $0.38
- Analyst Decision
- SNTG
- WINT Hold
- Analyst Count
- SNTG 0
- WINT 1
- Target Price
- SNTG N/A
- WINT $7.00
- AVG Volume (30 Days)
- SNTG 8.8K
- WINT 1.2M
- Earning Date
- SNTG 12-24-2024
- WINT 11-27-2024
- Dividend Yield
- SNTG N/A
- WINT N/A
- EPS Growth
- SNTG N/A
- WINT N/A
- EPS
- SNTG N/A
- WINT N/A
- Revenue
- SNTG $146,554.00
- WINT N/A
- Revenue This Year
- SNTG N/A
- WINT N/A
- Revenue Next Year
- SNTG N/A
- WINT N/A
- P/E Ratio
- SNTG N/A
- WINT N/A
- Revenue Growth
- SNTG N/A
- WINT N/A
- 52 Week Low
- SNTG $1.52
- WINT $0.33
- 52 Week High
- SNTG $8.45
- WINT $14.75
- Technical
- Relative Strength Index (RSI)
- SNTG 39.05
- WINT 30.45
- Support Level
- SNTG $1.88
- WINT $0.33
- Resistance Level
- SNTG $1.98
- WINT $0.42
- Average True Range (ATR)
- SNTG 0.10
- WINT 0.05
- MACD
- SNTG -0.00
- WINT 0.03
- Stochastic Oscillator
- SNTG 0.00
- WINT 11.11
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.